Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer acquisition plans

This article was originally published in The Tan Sheet

Executive Summary

Bayer is not turning away from pursuing growth in the consumer segment and will continue to look for "useful and value-adding transactions in our OTC portfolio," CEO Werner Wenning maintained during a March 24 conference call on the firm's plans to merge its existing pharmaceuticals division with Berlin-based Schering AG. Bayer announced a $17.47 bil. "white knight" bid for the specialty pharmaceutical firm March 23, thwarting a hostile acquisition attempt from Merck. The move follows existing strategy, Wenning said. "We always pointed out that it is our strategy to strengthen the specialty products business of our pharma division and expand our global position in the OTC business...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS099211

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel